Detalhe da pesquisa
1.
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.
Ann Oncol
; 34(8): 645-659, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269905
2.
Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG).
Gynecol Oncol
; 165(3): 637-641, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35393217
3.
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.
Ann Oncol
; 32(3): 337-350, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33455880
4.
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
Ann Oncol
; 31(11): 1506-1517, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32891793
5.
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.
Ann Oncol
; 29(4): 953-958, 2018 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29351573
6.
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.
Ann Oncol
; 29(5): 1108-1119, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29659677
7.
Networking for ovarian rare tumors: a significant breakthrough improving disease management.
Ann Oncol
; 28(6): 1274-1279, 2017 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28398524
8.
Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
Int J Cancer
; 138(9): 2274-80, 2016 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26649807
9.
Erratum to "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": Annals of Oncology 30; 2019: 1194-1220.
Ann Oncol
; 32(2): 284, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32912619
10.
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Ann Oncol
; 27(6): 1029-1034, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26961151
11.
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
Ann Oncol
; 32(12): 1475-1495, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34678411
12.
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
Ann Oncol
; 26(7): 1280-91, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26019189
13.
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
Ann Oncol
; 26(2): 259-71, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25214542
14.
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
Ann Oncol
; 31(12): 1623-1649, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32979513
15.
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).
Ann Oncol
; 26(5): 873-879, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25725046
16.
Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study.
Br J Cancer
; 110(11): 2728-37, 2014 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24800948
17.
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol
; 30(10): 1674, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31236598
18.
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol
; 30(8): 1194-1220, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31161190
19.
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry.
Ann Oncol
; 25(4): 773-780, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24351401
20.
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
Ann Oncol
; 25(8): 1570-7, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24827135